Industry
Biotechnology
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 09, 2024 | 10:02 am
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 12:07 pm
Portfolio Pulse from Benzinga Newsdesk
May 20, 2024 | 11:59 am
Portfolio Pulse from Benzinga Newsdesk
May 16, 2024 | 2:56 pm
Portfolio Pulse from Benzinga Newsdesk
May 14, 2024 | 2:40 pm
Portfolio Pulse from Benzinga Newsdesk
May 13, 2024 | 2:45 pm
Portfolio Pulse from Benzinga Newsdesk
May 10, 2024 | 12:02 pm
Portfolio Pulse from Benzinga Newsdesk
May 07, 2024 | 2:56 pm
Portfolio Pulse from Avi Kapoor
May 02, 2024 | 9:43 am
Portfolio Pulse from Avi Kapoor
April 29, 2024 | 5:04 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.